The 13th International Congress of the Immunology of Diabetes Society started this weekend in Lorne outside Melbourne in Australia. Almost 300 delegates from 21 countries are gathered from Dec 7 through Dec 11 to share and discuss the latest research in the field of type 1 diabetes and immunology. Several of Diamyd’s academic collaborators are presenting or chairing sessions at the meeting.

In the opening plenary lecture Dr Jay Skyler from the University of Miami stressed that the key to have an effect in type 1 diabetes is to simultaneously tackle the disease on several fronts by combining various therapeutics. He added that a key component of such combinations should be an autoantigen-specific therapy like the diabetes vaccine Diamyd^®.

“The IDS conference is a great opportunity to meet the key opinion leaders in the field of type 1 diabetes, many of them long term collaborators of Diamyd”, says Peter Zerhouni, CEO of Diamyd Medical. “Many of the topics presented and discussed at the meeting are directly related to Diamyd’s development projects applying immunological approaches to treat, prevent and cure type 1 diabetes.”

The Immunology of Diabetes Society is an international collaborative initiative set up to advance research related to the etiology, pathogenesis, prevention and cure of type 1 diabetes.

Read more about the Immunology of Diabetes Society here